- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
What We’re Reading: Menthol Cigarette Ban Lawsuit; ADHD Medication Shortage; Medicare Drug Price Negotiations Next Step
Antismoking groups sued the US government over the long-awaited menthol cigarette ban; the fill rate for Adderall and Vyvanse dropped more than 10% in 2 years despite soaring demand; the Biden administration has responded to offers from the manufacturers of drugs selected for Medicare pricing negotiations.
Lawsuit Seeks to Force Menthol Cigarette Ban After Months of Delays
Antismoking groups sued the US government on Tuesday over the long-awaited menthol cigarette ban, which the Biden administration has been delaying for months, according to the Associated Press. This lawsuit is the latest effort to force the government to ban menthol cigarettes, which are disproportionately used by young people and Black smokers; advocates are concerned that the federal plan could be derailed by election-year politics. Late last year, White House officials said they would take until March to review the rule. After the March deadline passed, 3 nonprofit groups, including Action on Smoking and Health, filed their lawsuit in a California federal court. A lawyer who helped file the lawsuit said the government will have about 2 months to respond.
More Americans Forgoing ADHD Medications as Shortages Drag On
A recent analysis found that the fill rate for Adderall and Vyvanse, 2 commonly prescribed drugs for attention-deficit/hyperactivity disorder (ADHD), dropped more than 10% in 2 years despite soaring demand, according to Axios. The ADHD drug shortage has occurred for nearly 18 months with no clear end in sight and is among many generic medicine shortages in recent years. Likely drivers of the shortages include drug production caps and pandemic-driven demand increases. The problem has recently been getting attention on Capitol Hill and from federal regulators. On Tuesday, HHS said in a white paper that statutory changes and more funding are needed for “more impactful and enduring solutions” than the ones it has already taken to address the shortages.
US Takes Next Step in Medicare Drug Price Negotiations
The Biden administration announced Tuesday that it has responded to offers from the manufacturers of 10 high-cost drugs selected for the Medicare drug pricing negotiations but provided no further details, according to Reuters. CMS picked the first 10 drugs for negotiation in August and sent its initial price offers in February. The companies had until March 1 to respond, and all did so. Each company can meet with CMS up to 3 times for further negotiations before a final price is announced on August 1. However, the negotiated prices will not come into effect until 2026. The drugs selected for negotiation are manufactured by Bristol Myers Squibb, Johnson & Johnson, Eli Lilly, Novo Nordisk, Pfizer, Merck & Co, AbbVie, Amgen, and Boehringer Ingelheim.
Navigating Health Policy in an Election Year: Insights From Dr Dennis Scanlon
April 2nd 2024On this episode of Managed Care Cast, we're talking with Dennis Scanlon, PhD, the editor in chief of The American Journal of Accountable Care®, about prior authorization, price transparency, the impact of health policy on the upcoming election, and more.
Listen
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
The Federal Trade Commission's (FTC's) vote to ban most employers from issuing and enforcing noncompete clauses could have varying impacts on the health care workforce; federal regulators vastly under-enforced antitrust laws in the hospital sector during the last 2 decades, resulting in increased health costs; the FDA recently found genetic evidence of the H5N1 bird flu virus in pasteurized commercially purchased milk.
Read More
